Contact Us
-
Diet Specialists
Categories
-
Recent Posts
- How Anant Ambani struggled from weight gain due to steroids from asthma treatment – The Times of India
- Usha Chilukuri says hubby Vance adapted her vegetarian diet and learned how to cook Indian food for his mom-in law – The Tribune India
- Instead of crisps, kids could eat snacks from the sea: the forager chef looking to revolutionise Chiles diet – The Guardian
- Banana to mushroom: How a plant-based diet can help you hair and overall well-being – The Times of India
- Is it possible to lose weight in just a few weeks through water fasting? All about the viral weight loss – The Times of India
Archives
Search Weight Loss Topics: |
Category Archives: Testosterone
Testosterone Replacement Therapy Market 2019: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast To 2025 -…
Posted: December 6, 2019 at 10:43 am
Industry Analysis of Testosterone Replacement Therapy Market
Testosterone replacement therapy (TRT) is a class of hormone replacement therapy in which androgens, often testosterone, are replaced. Testosterone replacement therapy (TRT) is an FDA-approved medical treatment for men of any age who have low testosterone, a hormone necessary for male sexual development.
Global Testosterone Replacement Therapy Market Study consists of the historical data to 2018 and forecasts until 2024. The report is created keeping in mind to make it a valuable source of information for market specialists in readily accessible documents. The documents are curated with clearly presented graphs and figures. Further, the scope of the report has covered a broad report on investigation of the general business, improvement openings, and regional and sub-local possibilities.
To Access PDF Sample Report, Click here: https://www.alexareports.com/report-sample/229377
Endo International, AbbVie, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals,
Based on demand and methods presently deployed by market key players, the global Testosterone Replacement Therapy Market report provides wisely analyzed and thorough and forecasts of the structured market growth rates in the future. For best analysis, the report divides the market into different segmentation product, application, and unmistakable techniques and frameworks of the global market Testosterone Replacement Therapy Market based on various parameters, including applications, product or service quality, and methods.
Based on Profile & Business Performance Outstanding Competitors in the market are Endo International, AbbVie, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals,.
Base On Types: 77
Base On Applications: Hospitals, Clinics, Others,
The research report highlights the size, share, trends and growth analysis of the Testosterone Replacement Therapy market on a global level.
Avail discount while purchasing this report @ https://www.alexareports.com/check-discount/229377
Endo International, AbbVie, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals,
Analysis based on competence and estimation of the global Testosterone Replacement Therapy Market is crafted through assess able methods to attain a clear insight of current and expected growth patterns. The report also contains the market distribution based on the geographical location around the globe and also the key markets such as United States, China, Japan and India.
The report answers the below mentioned key questions:
This data has been validated by the business investigators, giving huge bits of knowledge to the scientists, data analysts, directors, and other industry experts. The study deeply helps in understanding the market patterns, applications, determinations and industry obstacles.
Customization of the Report In case of any queries or customization requirements please connect with our sales team, who will ensure that your requirements are met.
Buy Full Report @ https://www.alexareports.com/checkout/229377
Endo International, AbbVie, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals,
About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data. Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.
Contact Us:Alexa ReportsPh no: +1-408-844-4624 / +91- 7030626939Email: sales@alexareports.comSite: https://www.alexareports.com
Here is the original post:
Testosterone Replacement Therapy Market 2019: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast To 2025 -...
Posted in Testosterone
Comments Off on Testosterone Replacement Therapy Market 2019: Global Key Players, Trends, Share, Industry Size, Segmentation, Opportunities, Forecast To 2025 -…
Are you ready for testosterone replacement therapy – KTAR.com
Posted: December 6, 2019 at 10:43 am
Are you ready for testosterone replacement therapy?
It is well known that testosterone plays a role in a mans sex drive, but this vital hormone does more than regulate libido and sperm production. It also has a role in regulating systems throughout the body.
It also affects bone and muscle mass, the way men store fat in the body, and even red blood cell production, according to Healthline. A mans testosterone levels can also affect his mood.
Symptoms of declining testosterone
Testosterone production maxes out in most men around age 17, and then levels stay relatively consistent for the next 10 to 20 years. Sometime between ages 30 and 40, its normal for men to experience a slow decline in testosterone production, averaging about 1% a year, according to Harvard Health.
You lose muscle mass, mental sharpness and libido (sex drive) begins to decline, viTal4men says.
Benefits of testosterone
Research has pinpointed other links between testosterone levels and memory. One study cited by Harvard Health found that World War II veterans who had high testosterone levels in midlife had better preserved tissue in some parts of the brain later in life.
Another study found that men with higher free testosterone levels achieved higher scores on four cognitive function tests, including visual and verbal memory, according to Harvard Health.
Testosterone replacement therapy aims to address the symptoms men experience from low testosterone levels and possibly help protect cognitive function in later life.
You may benefit from testosterone replacement therapy if any of the following apply:
Treatment options
The proper method of testosterone delivery for you is a matter for your physician to determine; however, many find that some gels tend to be messy and less convenient than other treatment modalities, viTal4men says.
These are typical treatment options, according to Harvard Health:
Most men feel improvement in symptoms within four to six weeks of taking testosterone replacement therapy, although changes like increases in muscle mass may take from three to six months, Harvard Health says.
Work with your doctor to find out whether you are experiencing symptoms of low testosterone. Misuse of testosterone can be dangerous, and injections should be administered only by healthcare professionals. Suddenly stopping testosterone treatment can also cause unpleasant withdrawal symptoms, according to drugs.com.
Schedule a free testosterone level test at vital4men.com, and find out if testosterone replacement therapy is right for you.
More:
Are you ready for testosterone replacement therapy - KTAR.com
Posted in Testosterone
Comments Off on Are you ready for testosterone replacement therapy – KTAR.com
Testosterone Replacement Therapy Market Share, Size 2019 Global Industry Analysis, Development, Future Growth, Top Manufacture, Revenue,…
Posted: December 6, 2019 at 10:43 am
Global Testosterone Replacement Therapy Market Research Report comprises holistic business information and changing trends in the market that enables users to spot the pin-point analysis of the market along with revenue, growth, and profit during the forecast period 2019-2024. It provides an in-depth study of the Testosterone Replacement Therapy market by using a SWOT analysis. This gives a complete analysis of drivers, restraints, and opportunities of the market.
Additionally, the Testosterone Replacement Therapy report provides an in-depth study of prime players at intervals the market by lightness their product description, business summary, and business strategy. It also endows with the quantity of production, Testosterone Replacement Therapy future demand, required raw material, and the money health of the organization.
Request a sample of this report at https://www.acquiremarketresearch.com/sample-request/229964/
Top prominent Players: AbbVie, Endo International, Eli lilly, Pfizer, Actavis (Allergan), Bayer, Novartis, Teva, Mylan, Upsher-Smith, Ferring Pharmaceuticals, Kyowa Kirin, Acerus Pharmaceuticals
By the Product-Types, it primarily split into: Gels, Injections, Patches
By End-Users/Application, this report covers: Hospitals, Clinics
Based on segmentation, the global Testosterone Replacement Therapy market report is made up of in-depth investigation of the leading regions, including North America, China, and Rest of Asia-Pacific, UK, Europe, Central & South America, and Middle East & Africa. The Testosterone Replacement Therapy research was provided for, including developments, leading growth status, landscape analysis, and segmentation with product types and applications.
Get Discount with this Report at https://www.acquiremarketresearch.com/discount-request/229964/
Reasons to Buy
1. To gain insightful analyses of the Testosterone Replacement Therapy Systems market from 2019 to 2024 and have a comprehensive understanding of the global market and its commercial landscape.2. To assess the production processes, Testosterone Replacement Therapy major issues, and solutions to mitigate the development risk.3. To understand the most affecting driving and restraining forces in the Testosterone Replacement Therapy Systems market from 2019 to 2024 and its impact in the global market.4. To understand the future outlook and prospects for the Testosterone Replacement Therapy Systems market from 2019 to 2024.
The report additionally focuses on international major leading trade players of the world Testosterone Replacement Therapy market providing data like company profiles, product image, and specification, price, capacity, cost, production, revenue and call data.
Upstream raw materials and instrumentality and downstream demand analysis are additionally administrated. With tables and figures helping analyze the worldwide Testosterone Replacement Therapy market, this research provides Testosterone Replacement Therapy statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Customization of this Report: This Testosterone Replacement Therapy report could be customized to the customers requirements. Please contact our sales professional [emailprotected], we will ensure you obtain the report which works for your needs.
See the article here:
Testosterone Replacement Therapy Market Share, Size 2019 Global Industry Analysis, Development, Future Growth, Top Manufacture, Revenue,...
Posted in Testosterone
Comments Off on Testosterone Replacement Therapy Market Share, Size 2019 Global Industry Analysis, Development, Future Growth, Top Manufacture, Revenue,…
Testosterone: What It Can And Can’t Do, Signs You’re Low, And How To Increase It – Men’s Health
Posted: December 6, 2019 at 10:43 am
Feeling tapped out? Foggy? Just not all that into sex? Gotta be your testosterone, some people would have you believe. And were believing it, too, with interest and investment in T-boosters and T-supplements rising steadily in the past decade.
Dont get us wrong: testosterone is one critical hormone. Babies first encounter it in utero, when it triggers the differentiation of boys from girls. In puberty, it contributes to your bone growth and muscle mass, and continues to affect functions including your red-blood-cell production and mood stability.
But the message certain vested interests are sending plays right into the economic and social anxieties men are facing. Its like when anti anxiety meds such as Valium first came onto the scene, says urologist Elizabeth Kavaler. All these middle-aged women were addicted to Valium, because that was the solution to everything. Testosterone has become the new answer for a life of quiet desperation. More and more of us are feeling the exhaustion of uneasiness. We are being asked to do more with less. Were just trying to get through the day alive. Men think, Well, if I just get a little testosterone, Im going to feel great! Kavaler says. And thats not the case.
Theres so much information out there about T much of it speculation and lore that leads us to jump to conclusions about it. Men put all kinds of psychological weight on their testosterone number a low one makes you think youre somehow less manly; a high one means youre basically LeBron James and thats where we get things wrong. Theres little evidence for those stereotypes. Low doesnt automatically imply youre weak or retiring; high doesnt guarantee you muscles or MVP athletic performance.
A low number might not even be a low number for very long. It might just indicate that you havent been treating yourself very well. A high number doesnt mean youre programmed to be aggressive. As long as your T is in the normal range, theres nothing about a high number thats better than a low one, or vice versa. In the name of science and good journalism, I got my testosterone tested twice while writing this story.
It put my assumptions up against a pretty big test, too. What do you really know about this famous hormone? Here, we break down the best and latest information to give you the clearest picture yet of what T means for you.
IT CAN...
BUT TOO MUCH ALSO CAN...
IT CANT...
BUT IT ALSO CANT...
You should have at least two blood tests, since T is constantly in flux. It peaks in the morning, so if youre young and on a typical sleeping schedule, aim to be tested by 10am. If youre over 50, it doesnt matter as much. Also note: vitamins with biotin can lower your score, so skip them for three days before testing.
A T level of 8.64 to 29 nanomoles per litre of blood is considered normal. If you are close to 8.64 and you feel fine, then youre no less healthy than a guy whose level is 35 and also feels fine. Theres an exception to that, though. (See What the Numbers Mean.)
I got my first test at the tail end of a busy week. Id slept less than five hours the night before, then scrambled to the phlebotomist in a daze. My number: 9.9. Thats in the normal range, but just barely. I have no symptoms of low T, but it was hard to shake the feeling that there was something wrong with me, even though I know that normal is normal, no matter where it is in that range. Eleven days later, I was tested again. My number was 14.8. Why such a dramatic change? It might be because Id slept better and cut out my multivitamins. Irrational or not, I felt like more of a man. The whole experience was a microcosm of our relationship with T. We act like its destiny, but its just biology easily misunderstood and more varied than we think.
Common symptoms of below-normal t, which could affect as many as 500,000 men in Australia (generally older men):
1. Lack of energy
Youre lethargic not like you didnt get enough sleep last night but like no matter what you do, you never feel rested.
2. A paunch
Having a dad bod doesnt mean you have low T but it could be one indicator.
3. Lack of libido
Sort of. Its the lack of your base level sex drive that sudden feeling of being turned on by the sexy person you spot on the street that indicates low T, according to Dr Tobias Kohler, of the Mayo Clinic. Its not considered low libido when you dont want to have sex on a Thursday night after youve been crushed by work all week.
4. Erectile problems
Only precipitously low T will keep you limp. But if you have problems getting it up, you may have other issues to solve, which may require a visit to a doctor. Or a little blue pill. Or couples therapy
If your t is truly low youve got three courses of action, says mills, in order of increasing aggressiveness. choose wisely.
1. Lifestyle Adjustment
The single best thing you can do to improve your level is be healthier. Avoid stress, get more sleep and lose weight an enzyme in fat tissue converts testosterone to estrogen. Thats one reason flab can lower your T. Its also why overweight guys can develop man boobs, and why bodybuilders who juice can also develop man boobs they dont have much fat, but theyve jacked their T levels so high that theres a lot of it available to be turned into estrogen. Thinking of T strictly as the male sex hormone oversimplifies the complex hormonal interactions that make our bodies work. Which is also why, if you can avoid it, you dont want to go with the needle-in-the-butt routine to raise your T.
2. A Testicle Stimulant (plus lifestyle adjustment)
If your level is low enough to warrant more aggressive treatment, your doctor can prescribe a drug that causes your pituitary to tell your gonads to make more testosterone. The typical choice is clomiphene citrate (Clomid), a common fertility drug for women. Using it doesnt exempt you from needing to get healthy, though, as it doesnt diminish the risk of losing T to bad sleep and a beer belly.
3. Testosterone Replacement Therapy (and yes, youll still need to adjust your lifestyle)
This should be your last resort. When you give your body T, it stops making its own, and theres no guarantee it can start again. Before you replace it, find a doctor who can help you choose from the following delivery systems (see right), and be glad that weve moved past the early days of replacement therapies, like one in the 1920s that involved transplanting goat testicles into men.
Read the original post:
Testosterone: What It Can And Can't Do, Signs You're Low, And How To Increase It - Men's Health
Posted in Testosterone
Comments Off on Testosterone: What It Can And Can’t Do, Signs You’re Low, And How To Increase It – Men’s Health
Hormone Replacement Therapy (HRT) Market to Grow with an Impressive CAGR by 2025 | Amgen, Inc., Novo Nordisk, Eli Lily – The Raleigh Recorder
Posted: December 6, 2019 at 10:43 am
A Profession Intelligence Report published with the title Hormone Replacement Therapy (HRT) Market has given an in-depth information about Hormone Replacement Therapy (HRT) Market economy to readers.
This report makes readers aware about data which covers price, revenue, gross profit, interview record, business distribution among others. This will help readers to know about market key players in a better manner. The report comprises of regional development status, covering all the major regions of the world. This regional status shows size (in terms of value and volume), and price data for Hormone Replacement Therapy (HRT) Market.
Hormone Replacement Therapy (HRT) Market Report presents a dynamic vision to conclude and research market size, market hope and competitive environment. The study is derived from primary and secondary statistical data and consists of qualitative and numerical analysis.
The main company in this survey is: Amgen, Inc., Novo Nordisk, Eli Lily, Abbott, and Genentech
To obtain a Sample copy of this Hormone Replacement Therapy (HRT) report, Click [emailprotected]https://www.analystviewmarketinsights.com/request_sample/AV181
By the Replacement therapy, the market is primarily split into: Estrogen, Human Growth Hormone, Testosterone, Thyroid,
By the Route of Administration, the market is primarily split into: Parenteral, Oral, Transdermal, Other,
By the Disease, the market is primarily split into: Male Hypogonadism, Menopause, Hypothyroidism, Growth Hormone Deficiency, Others,
As per the report the Hormone Replacement Therapy (HRT)industryreached at its zenith till 2018. It is made after in-depth study of the market. The analysis reveals that the leading segments have established their reputation in the market and the insights will help them to come up with new strategies. In short this report will be valuable for those who have unbiased information about stakeholders, investors, product managers, marketing executives, and supply, demand, and future predictions.
The report also provides exhaustive PEST analysis for regions namely; North America, U.S., Canada, Europe, and Asia Pacific after evaluating political, economic, social and technological factors for the Hormone Replacement Therapy (HRT) Market.
Research Methodology:
Primary Research:
The facts mentioned in the report is gathered from the Hormone Replacement Therapy (HRT) industryexperts. These experts are management organizations, processing organizations, analytic service providers of the industrys value chain. Interviews are conducted with all these experts to take out quality information from them for knowing the future prospects of the market.
In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEO, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Hormone Replacement Therapy (HRT) industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.
Secondary Research:
In the Secondary research crucial information about the industries value chain, total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology-oriented perspectives.
Read detailed report highlight for Hormone Replacement Therapy (HRT) repor@ https://www.analystviewmarketinsights.com/report-highlight-hormone-replacement-therapy-hrt-market
Reasons to Buy This Report
Buy Full Report @ https://www.analystviewmarketinsights.com/product/hormone-replacement-therapy-hrt-market
Please contact our sales professional [emailprotected], we will ensure you obtain the report which works for your needs.
Posted in Testosterone
Comments Off on Hormone Replacement Therapy (HRT) Market to Grow with an Impressive CAGR by 2025 | Amgen, Inc., Novo Nordisk, Eli Lily – The Raleigh Recorder
Gender identity is hard but jumping to medical solutions is worse – The Economist
Posted: December 3, 2019 at 8:44 pm
This is a guest contribution for The Economists Open Future initiative, which aims to foster a global conversation on the challenges of the 21st century. More Open Future articles are at Economist.com/openfuture
* * *
The day I knew I should quit my job answering phones at the transgender health-care clinic in California was the day a caller (lets use the name Betty) threatened her in-home caretaker with a knife during the call. As the caretaker begged our clinics nurse to track down Bettys doctor and tell him that Betty was having a psychotic episode, Betty stood between her and the apartments front door with a kitchen knife. Betty had poorly controlled paranoid schizophrenia, and often called the clinic agitated, alternately whispering and screaming about government agents stalking her. Betty was also a trans woman whom most people regarded as male, the sex of her birth.
Upgrade your inbox and get our Daily Dispatch and Editor's Picks.
The clinic followed the informed-consent protocol: its mission was to provide transgender patients who otherwise lacked access to health care with injections, skin patches and pills of feminising or masculinising hormones without having to pass through a series of requirements and assessmentsknown as gatekeepingthat restricted access in the past.
In medicine broadly, informed-consent refers to the ethical requirement that a clinician administering a treatment communicate to the patient the anticipated risks and benefits, as well as reasonable alternatives to the treatment. Yet for transition medicine in America, informed-consent programmes do not require clinical documentation, beyond patient reports, of the patients gender dysphoria over time (ie, a feeling of mismatch between ones biological sex and gender identity) and readiness for medical interventions.
Gatekeeping horror stories are notorious in the transgender community. In the past it was not unusual for a trans person to be told by doctors and psychologists they would not be referred for hormones because they were not visually appealing as their preferred gender, werent interested in dating the opposite gender, or had unresolved mental-health problems (some of which are predictable responses to experiencing transphobia, such as anxiety and depression).
It was not unusual for a trans person to be told they would not be referred for hormones because they were not visually appealing
Pioneering LGBT health centres across America developed informed-consent protocols for hormone treatment in a well-intentioned effort to imbue the experience of pursuing hormone treatment with dignity for patients. But as informed-consent protocols have become the norm rather than the exception, we may be shunting transgender people in America into a parallel medical systemone in which patients bargain away careful assessment and education for greater autonomy and shortened timelines to access medical treatments.
At my clinic, we were informed-consent true-believers. We didnt badger you with questions; as long as you were 18, even if you had no way to pay the clinics fees, you would get your hormones. You had to sign forms stating that you understood that although hormone-replacement therapy (HRT) benefits many trans people suffering from gender dysphoria, the health risks are largely unknown. Starting hormones could have negative consequences for your mental well-being, social functioning and even the intensity of your gender dysphoria (many people find that their distress about a body part like their breasts will only increase when the effects of testosterone appear, such as facial hair).
Also, people were informed that they were waiving the mental-health screening recommended by the World Professional Association for Transgender Health. Its standard of care recommends that patients seeking HRT be screened for schizotypal disorders, autism-spectrum disorders, personality disorders, dissociative disorders, post-traumatic stress disorders and more.
In the case of Betty, I felt that the clinic where I worked wasnt sufficiently concerned whether her mental disorder created delusions that often controlled her life, or meant she was so cognitively disabled that transition predictably left her more isolated and chronically stressed than before she started HRT. The medical staffs attitude towards Betty and many of the other patients who were receiving hormones while managing (or failing to manage) severe mental illness was a profound lack of interest about whether one affected the other.
We were informed-consent true-believers. We didnt badger you with questions; as long as you were 18, you would get your hormones.
In fact, most of us worked there because we rejected the idea that a strongly felt internal sense of gender could be a symptom of mental illness. That shared, ideological foundation meant it was verboten for the staff to consider whether the HRT might be exacerbating Bettys schizophrenic symptoms or making it harder for her to build the basic social relationships that provide the support and positive feedback that is so necessary for mental health. If the HRT did not actually assist Betty in presenting as a woman or improve her functioningand it seemed to be doing neitherwe considered affirming her identity more important than those conventional measures of the treatments effectiveness.
The most radical and liberatory action we could take was to affirm Bettys identity. If we were the one and only place she visited in her day where she was referred to using her chosen pronouns, we considered it paramount we gave her that experience. This commitment to affirming identity through correct pronouns and easy HRT was our reason for being. But strangely, by fulfilling our commitment to affirming felt identity, we seemed to be off the hook for questioning whether we were doing all we could to avoid harming her.
I quit the clinic in 2014, and in 2016 I spoke to the lawyer of a patient suing that same clinic. This patient also pursued HRT while experiencing intense delusional symptomsit was 2012 and he thought the world was ending. The clinic, affirming as ever, recommended and provided the referral letters for him to have an orchiectomy, a removal of his testicles, which he underwent. When his delusional symptoms eventually abated he detransitioned, coming to an uneasy peace being, and presenting as, male.
I know him because we are both detransitioned people. I was also convinced that I was a trans personas a result of misunderstanding a persistent sense that my body felt unreal, a common dissociative symptom following traumaand received HRT at this same clinic, taking testosterone for nine months. For the past five years Ive been a part of a growing community of detransitioned people who are speaking out about questionable norms and practices in transgender medicine.
The clinic, affirming as ever, provided the referral letters for him to have an orchiectomy, a removal of his testicles
When I first detransitioned, my community consisted of online groups of fewer than 100 women. Five years later the detransition discussion-forum on the popular site Reddit has just hit 7,000 people of both sexes. I know detransitioned people who later discovered they had autism-spectrum disorders, detransitioned people who came to recognise that they were experiencing traumatic dissociation, even detransitioned people who had such severe dissociation that they had multiple alters (ie, multiple identities) while being treated with hormones and surgeries.
Our stories, if taken seriously, could help improve the state of transgender health careparticularly at informed-consent clinics, which are becoming the norm at American colleges, LGBT health centres and recently many Planned Parenthoods. Instead we are ignored, compared to ex-gay Christians or treated as political footballs. (I was particularly disheartened when Ryan Anderson, a fellow at the Heritage Foundation, a conservative think-tank, used my and other detransitioners stories in his book that was critical of LGBT and feminist issues, When Harry Became Sally.)
That is because the burgeoning orthodoxy on the left is that detransition is so rare that only transphobes care about it. If you draw attention to the stories of transition gone wrong, the thinking goes, there will be less public support for transition and for transgender people themselves. For academic researchers and journalists, telling our stories is a fast track to being labelled a transphobe. This has profound consequences for what we know about the medical paths that leads to detransition.
In fact, we have no idea how prevalent detransition is in America. The most widely used estimate, that 2.2% of people who transition later detransition, comes from a study in a completely different place (Sweden) and time (1960-2010), when gatekeeping was much stricter. Moreover, that study defined a detransitioner as someone who had changed their name and gender legally (an arduous process in Sweden at the time) and then had the motivation and money to go through the name change process in reverse, a standard so strict that I wouldnt be counted, and nor would 90% of the detransitioners I know.
If you draw attention to the stories of transition gone wrong, the thinking goes, there will be less public support for transgender people
This passionate but misguided argumentthat detransition is extremely rare, thus any research into it is harmful and motivated by transphobiahas led to outright censorship. In 2017 Bath Spa University in Britain shot down a research proposal that sought simply to collect stories from detransitioners. The same year the Philadelphia Trans Health Conference, a major annual gathering of the transgender health community, abruptly cancelled two previously approved panels that I had helped organise on detransition and alternative methods of managing gender dysphoria, because of the level of heated conversation and controversy. These were just two out of nearly 200 sessions.
As a result, the subject of detransitioners health-care experiences remains virtually untouched by academic researchers. This shows in the clumsy approaches of those few researchers willing to engage the subject. For example, a poster presented this summer at the European Professional Association of Transgender Health conference purported to show a very low rate of detransition and regret (0.47%) at an NHS clinic in London. The poster bounced all over social media, cited as proof that detransition is indeed exceptionally rare.
But that estimate was generated by combing through case files for patients who returned to the clinic to inform staff of their detransition or regret. The thing is, though, detransitioners almost never do this. This is widely known within the communitywhy would you go back to a clinic or to a doctor who, in your view, helped you hurt yourself?
Apart from the few who sue their doctors and therapists, detransitioners tend simply to disappear from a clinics view, despite often having urgent needs for continued medical treatment and therapy. I have heard of only three detransitioners who went back to talk to the clinicians who had assisted them in transitioning. (The experience of one who did just that convinced me that I probably never will.) Nor do they tend to go to other clinics for follow-on care: they simply become invisible.
The majority of the studies supporting the conclusion that medical transition yields positive outcomesand there are manyfollowed patients in highly structured clinical programmes that provided comprehensive assessments. But when I searched last February for programmes that met that careful standard in America, I wasnt able to find one. No one knows whether informed-consent protocols will yield the same success rate, but the stories Ive heard during the past five years make me profoundly sceptical.
In a comprehensive examination of peer-reviewed articles on medical-transition between 1991 and 2017 by researchers art Cornell University, called What We Know, there have been no studies tracking a cohort of patients at an informed-consent clinic over time to investigate the outcomes that their protocol produces. Moreover, there have been no studies on what percentage of clinics in America follow the standard of care recommended by the World Professional Association for Transgender Health versus their own informed-consent protocols.
From the point of view of clinics, they would respond to the criticisms by noting that informed-consent clinics often serve a poor and transient population, which presents challenges to following up with patients. Another difficulty is that transgender medicine is a relatively new field serving a small minority of the population, necessarily limiting funding and opportunities for research. As to whether informed-consent policies have the effect of leading people to medical interventions too soon, they would argue that the people who end up feeling ill-served by the high level of patient autonomy will always be a small minority.
Yet this does not obviate the need for better practices. I dont want informed-consent clinics shuttered. I want them to do the tasks normally associated with medical care. This includes giving patients access to differential diagnosis (distinguishing between conditions that share similar symptoms) and follow-up research so that providers can improve the care they offer.
There is a responsible path between making transgender people jump through hoops and allowing people experiencing psychosis to have their testicles removed
For example, ensuring that low-cost psychology referrals are offered to all patients seeking informed-consent care could increase voluntary participation in comprehensive evaluations. Ensuring that staff are trained to identify patients showing signs of certain severe disorders, and to provide psychological evaluations when appropriate, could help prevent outcomes like Bettys.
Even ensuring that all clinics have counselling referrals on hand would be a step in the right direction. Although I received a prescription for hormones by my second visit, many patients sat on the waiting list for counselling from the same clinics social workers for more than five months and when I requested an outside referral, I was told to google the phone number of a local counselling internship site.
There is a responsible middle path between making transgender people jump through hoops to access needed medical care and allowing people experiencing psychosis and delusions to have their testicles removed. Until gender care providers accept their ethical responsibility to find that path, the American medical system continues to serve this community of people poorlybut this time, this neglect is designed and perpetrated by allies under the banner of transgender rights.
_________________
Carey Callahan is a family therapist and board member of the Gender Care Consumer Advocacy Network, a non-profit group that advocates for the rights and welfare of consumers of gender care services.
More:
Gender identity is hard but jumping to medical solutions is worse - The Economist
Posted in Testosterone
Comments Off on Gender identity is hard but jumping to medical solutions is worse – The Economist
Cracking the code of bias against trans athletes – Outsports
Posted: December 3, 2019 at 8:44 pm
Transgender participation in sport has come to the forefront in the last few years at all levels, from youth leagues to the Olympics. And thats led to backlash from many groups and individuals who are supported by and stand up for those who have always maintained an anti-LGBTQ position.
On November 20, Outsports contributor Ken Schultz looked into whats behind a recent poll by Rasmussen, which concluded a majority of Americans oppose transgender inclusion in sports.
What he found were polling methods and loaded questions with terms that slant toward creating results opposing trans inclusion.
In his analysis, Schultz stated: In order to move the debate in that more inclusive direction, we need to educate the public on these kinds of biased euphemisms and anti-trans code words that transphobes use to sway public opinion.
As a sports journalist, a sports fan and as a participating transgender athlete, I couldnt agree more with my Outsports colleague. When you look in the transphobes playbook, you find a number of varied tactics designed to make bigotry look reasonable.
My examination here will look at a recent piece of propaganda making the rounds and the tactics it employs. The poster below was created by an operative for an anti-trans organization.
Willful, deliberate misgendering is a critical piece of this con game. The quote used at the top of this image is an example of the conditioning. Its also the tactic of websites such as Breitbart, The Blaze and RedState, who ruthlessly target transgender female athletes. Consider the example of cyclist Dr. Veronica McKinnon, who is one of the most targeted trans athletes in the world right now, ever since winning her first UCI Masters track cycling championship in 2018. She had barely reached the winners podium when the clickbaiter sites screamed headlines such as Man Pedals Faster at the Womens World Cycling Championships, and Transgender female cyclist place first against biological women
The body copy of their articles stays with this theme. There is consistent use of terms such as biological males and biological females, which is passive-aggressive misgendering. Some sites dont even bother with such backhanded attempts, and neither do the professional political transphobe groups. In the Alliance Defending Freedoms complaint to the Department of Education concerning Connecticut high school athletes Andraya Yearwood and Terry Miller, the 29-page document consistently refers to both girls as boys and biological males.
You will rarely if ever see attacks directed at Patricio Manuel (above), or at Chris Mosier, or any transgender male athletes with this piece of propaganda, or any piece by the anti-trans lobby. This is by design. Transgender male athletes dont sell the narrative that transphobes are trying to sell. This is about more than sport to the anti-lgbtq and anti-human rights lobby. It also shows the misogyny of the people who are behind the curtain. The main message here is transgender women are not women and cisgender women are too inept to compete successfully in sport.
Lies of omission are a centerpiece tactic of the anti-trans crowd. The most used is the matter of regulations. They intensely try to sell the idea that men wake up one morning, say they are a woman and play womens sports. Yet they know that there are extensive rules and regulations that transgender athletes must follow to the letter, like every athlete.
For example, consider the case of Southern Illinois swimmer Natalie Fahey. Below is the NCAA regulation that applies to her case.
A trans female (MTF) student-athlete being treated with testosterone suppression medication for Gender Identity Disorder or gender dysphoria and/or Transsexualism, for the purposes of NCAA competition may continue to compete on a mens team but may not compete on a womens team without changing it to a mixed team status until completing one calendar year of testosterone suppression treatment.
There are also lies of omission in terms of context and backstory. Fahey continued to compete during that interim year on the mens team at SIU. When she met the NCAAs regulations and began competing as a woman, she was entered as an exhibition swimmer and her finishes did not count in the overall team standings at the conference championship meet because of the timing when she became eligible to compete. This is the crucial context that the anti-trans lobby will ignore because it wrecks the narrative they are trying to sell.
One can also look the case of an athlete such as 2019 Division II national 400 meter hurdles champion CeC Telfer, who took a year off from competition while starting hormone replacement therapy and then returned to active competition after fulfilling the NCAA requirements. Again, this is what the other side wont tell you.
At times, the other side will just flat-out lie.
How New Zealand weightlifter Laurel Hubbard is portrayed here is a textbook example. The propaganda here and in other places is that she is a world champion. She has never won a world championship. At the 2017 world weightlifting championships she won two silver medals. The anti-trans crowd relies upon the fact that most readers and/or sports fans will not bother to check the facts for themselves, in part, because the sport is more obscure. Keep that in mind as we consider:
Consider how roller derby athletes are mentioned in this piece above. They are attacking perhaps the most trans-inclusive sport in the world. Noted TERF writer Emma Chesworth recently learned that this is not a good idea, when she wrote an article critical of widespread policies of inclusion in roller derby. Teams and leagues in the US and UK lit up Twitter in a vigorous defense of their sport.
Fact checking would have perhaps saved Chesworth some embarrassment, but thats the rub here. A transphobe counts on the general public to not research the claims for themselves.
Notice also that most of the targets pictured on the anti-trans poster come from sports that are out of the mainstream. This type of propaganda also tends to focus on small college and high school athletes because it is easier to bend a story fewer people actively know about.
The propaganda poster here was built by an operative representing Hand Across The Aisle Women. They characterize themselves as radical feminists, lesbians, Christians and conservatives that are tabling our ideological differences to stand in solidarity against gender identity legislation.
But they are allied with groups including the Heritage Foundation, the Family Research Council, and the Alliance Defending Freedom. These are among most influential anti-womens rights and anti-LGBTQ lobbies in the world. Both the FRC and the ADF are also classified as anti-LGBTQ hate groups by the Southern Poverty Law Center.
Scratch the surface of many of these radical feminists and you are finding greater synergies with groups that have made their name by demonizing feminism for decades, and the media mouthpieces like a Breitbart or the Blaze.
Why does this matter? Because this isnt only about sports, just like the headline-making battles in Houston, Texas and North Carolina were not only about bathrooms, and the anti-LGBTQ lobby does not deny this.
This is one of the few fronts they are fighting in a larger battle that legally and culturally they are losing, and they admit to it. Theyve even admitted that the bathroom hysteria was deliberately built to scare people, even though the stats dont fit the hysteria.
Such is the fulcrum lifting three cases pending in the U.S. Supreme Court right now that could redefine a whole spectrum of human rights issues for all LGBTQ citizens.
The real match here is inclusion versus erasure, and it's a match we transgender Americans cannot afford to lose.
See original here:
Cracking the code of bias against trans athletes - Outsports
Posted in Testosterone
Comments Off on Cracking the code of bias against trans athletes – Outsports
Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational – Yahoo Finance
Posted: December 3, 2019 at 8:43 pm
TORONTO--(BUSINESS WIRE)--
Acerus Pharmaceuticals Corporation (TSX:ASP, OTCQB:ASPCF) today announced that the revised commercial partnership agreement with Aytu Bioscience (Aytu) to accelerate the growth of NATESTO in the United States is now closed and fully effective as of December 1, 2019. Both parties have mutually waived the closing conditions of the revised partnership agreement, including the requirement that Acerus complete a raise of a minimum of USD 10 million on or before the end of January 2020, enabling Acerus to launch a U.S.-based specialty sales force, which will promote NATESTO to urologists and endocrinologists. Aytu will continue to book all NATESTO revenue in the United States and they will promote NATESTO to all other specialties including internal medicine and family practice.
To accelerate the launch of Acerus U.S. commercial team, Aytu has agreed to transfer 5 current sales personnel to Acerus as of December 2, 2019. These staff will operate as Acerus employees but they will remain on Aytus payroll until the earlier of the date on which Acerus is ready to fully assume the personnel or June 30, 2020. Aytu will deduct the costs of these sales personnel from quarterly payments otherwise owed to Acerus under the revised agreement, with a final accounting to be done once per year. Throughout 2020, Acerus will be building out a complete US-based specialty care sales force and other commercial functions, significantly increasing the number of employees working directly on NATESTO in the United States.
This co-promotion is expected to significantly increase sales force coverage of targeted U.S. prescribers, putting a higher promotional focus on urologists and endocrinologists, while enabling Aytu to focus its promotional efforts in primary care and other specialties.
Acerus is extremely pleased to see our revised partnership with Aytu moving to execution mode as we strongly believe that the performance of NATESTO in the U.S. will benefit from an enhanced commercial focus on urology and endocrinology, said Ed Gudaitis, President and Chief Executive Officer of Acerus. We are happy to welcome the former Aytu staff to the Acerus team. With this revised partnership, Acerus is effectively pivoting its focus of effort to the U.S. NATESTO opportunity. As such, we have implemented a resource reallocation program within our Canadian office that has led to a greater than 50% reduction in headcount so that we can align our SG&A spend appropriately.
On July 29, 2019 the companies agreed to expand their commercial partnership and amend and restate the original 2016 NATESTO exclusive U.S. license agreement. Under the terms of the new agreement, Aytu returns the NDA for NATESTO in the U.S. back to Acerus. Going forward Acerus will assume all regulatory and clinical responsibilities and costs for the product in the U.S. Acerus will take on a more expansive role in matters such as U.S. marketing, reimbursement and medical strategy as part of the companies joint commercialization committee, and will launch a specialist sales force focused on urologists and endocrinologists (Acerus Sales Channel). Aytu will retain its primary care sales force (Aytu Sales Channel) and will continue to book all product net revenue while serving as the exclusive U.S. supplier of NATESTO to wholesalers, pharmacies and other customers that receive a direct shipment. Financial payments will be based upon a tiered level of net revenue, post cost of goods sold (COGS), based on annual sales performance in the respective Acerus and Aytu Sales Channels.
To establish a high performing commercial footprint in the U.S., Acerus has engaged Syneos Health (SYNH), a leading integrated biopharmaceutical solutions organization including the industrys largest Contract Commercial Organization (CCO), to be its commercialization partner. Syneos Health has extensive experience in Mens Health and with NATESTO, and offers an end-to-end model that will enable Acerus to rapidly stand up a U.S. commercial team; to scale across all aspects of commercialization, including medical and regulatory affairs, managed markets, marketing and sales; and will provide greater flexibility and effectiveness in resource deployment.
Story continues
Low testosterone is estimated to affect approximately 39% of men over 45 years old in the U.S.; however, because the condition is underdiagnosed the overall prevalence is uncertain1. While patients have access to other treatment options, NATESTO is unique in that it is administered in seconds via a convenient and simple nasal gel applicator, addressing the risk of testosterone transference associated with other topical products, which carry black box warnings on their product labels.
About NATESTO (Testosterone) Nasal Gel
NATESTO is a nasal gel formulation of testosterone developed by Acerus Pharmaceutical Corporation and indicated as a replacement therapy for men diagnosed with conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). It is the first and only nasally-administered testosterone product approved by the U.S. Food and Drug Administration, Health Canada and South Korea Ministry of Food and Drug Safety (MFDS), available in a no-touch dispenser with a metered dose pump. A copy of the NATESTO Canadian product monograph can be found at: http://www.aceruspharma.com/English/products-and-pipeline/NATESTO /default.aspx. For further information, specific to the U.S. product dosing and administration, please visit: http://www.NATESTO .com.
About Acerus
Acerus Pharmaceuticals Corporation is a Canadian-based specialty pharmaceutical company focused on the commercialization and development of innovative prescription products that improve patient experience, with a primary focus in the field of mens health. The Company commercializes its products via its own salesforce in Canada, and through a global network of licensed distributors in the U.S. and other territories.
Acerus shares trade on TSX under the symbol ASP and on OTCQB under the symbol ASPCF. For more information, visit http://www.aceruspharma.com and follow us on Twitter and LinkedIn.
Notice Regarding Forward-Looking Statements
Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the commercial performance of NATESTO in the United States, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 4, 2019 which is available at http://www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
1 Mulligan T, Frick MF, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006 Jul 1; 60(7): 762769
View source version on businesswire.com: https://www.businesswire.com/news/home/20191202005215/en/
Read this article:
Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational - Yahoo Finance
Posted in Testosterone
Comments Off on Expanded U.S. NATETSO Partnership Between Acerus Pharmaceuticals and Aytu BioScience Is Now Fully Operational – Yahoo Finance
Testosterone Replacement Therapy Market : Global Competitive Analytics and Insights 2016 2024 – Downey Magazine
Posted: December 2, 2019 at 2:43 am
The global market for testosterone replacement therapy is characterized by the presence of a large number of small and large scale manufacturers. All of the manufacturers have been steadfast in filling the meagre market gap in order to enhance their prospects of growth.
Furthermore, research and development has been the central characteristic of al the market players operating in the global market. In 2015, it was found that 80% of the total market share was held by the top five market vendors with AbbVie Inc. taking the lead. The large scale vendors are focusing on establishing an iconic brand for their product by resorting to rigorous marketing and advertising tactics. The smaller companies are expected to concentrate on capturing the local and regional markets to sustain themselves in the current scenario of stiff competition.
Obtain Report Details @https://www.transparencymarketresearch.com/testosterone-replacement-therapy.html
A negative implication for the leading market players in recent times has been the loss of patents for their products. This has not only plundered them of revenues but has also affected the workflow of these companies. The market players are expected to launch awareness campaigns about testosterone replacement therapies in order to educate and inform the consumers. Hence, the market for testosterone replacement therapies is expected to witness the emergence of several new trends and opportunities over the forthcoming years. Some of the key players in the global testosterone replacement therapy market include Bayer AG, Endo Pharmaceuticals, Inc., Novartis AG, and Allergen plc.
The CAGR for theglobal testosterone replacement therapy marketis estimated to be -4.20% over the period between 2016 and 2024. The negative growth rate of the global market is expected to take the market value from US2.0 bn in 2015 to a decreased value of US$1.3 bn by 2024-end.
Request PDF Sample of Testosterone Replacement Therapy Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1097
High Incidence of Hypogonadism to Drive Market Demand
Research studies suggest that around 30% of all men suffer from testosterone deficiency, which has driven demand within the global market for testosterone replacement therapy. Furthermore, the population demographic of men in the age range of 40-79 years is more likely to suffer from testosterone deficiency. The need for mutation or having an offspring amongst men in the aforementioned age range has driven demand within the global market.
Moreover, the geriatric population has been on a rise, which underhandedly contributes to market growth. Several campaigns aimed at educating people about the benefits of testosterone replacement therapy have been an important propeller of demand within the global market. It is anticipated that more people suffering from testosterone deficiency would resort to these therapies over the coming years.
Enquiry for Discount on Testosterone Replacement Therapy Market Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=1097
Side Effects of Testosterone Replacement Therapy Could Obstruct Market Growth
Despite the rising awareness amongst the masses about the advantages of testosterone replacement therapies, the market growth is hindered by the apprehension of the people. The chances of developing metabolic disorders are higher in men who undergo testosterone replacement therapies. Furthermore, the risk of developing cardiovascular diseases also discourages people from resorting to testosterone replacement therapies. The FDA has also cautioned people about the use of such therapies by issuing strict warnings, which has further obstructed the growth of the global market.
Read more here:
Testosterone Replacement Therapy Market : Global Competitive Analytics and Insights 2016 2024 - Downey Magazine
Posted in Testosterone
Comments Off on Testosterone Replacement Therapy Market : Global Competitive Analytics and Insights 2016 2024 – Downey Magazine
Best of the Red River Valley 2019: Best Cosmetic/Esthetic Clinic – INFORUM
Posted: November 30, 2019 at 9:45 pm
Winner: Rejuv Medical Aesthetic Clinic
Location: Fargo
"The secret to our success: it's all about team," Melissa Rogne, Rejuv founder and president, said. "We have a phenomenal team with a shared purpose of sparking joy for our patients. As a patient, you can feel this difference when you enter Rejuv. The atmosphere is fun, upbeat and makes you want to return."
Rejuv offers a plethora of different services, including skin care treatments, injectable treatments, laser treatments, full-service dermatology and body and wellness.
"Our newest addition to our anti-aging arsenal are PDO thread lifts; this service is amazing for anyone looking for a facelift without the surgery," Rogne said. "It's important for people to know we provide the full spectrum of optimal aging services from testosterone replacement therapy for men and women to Botox and fillers. We don't only help you look your best, our mission is to make sure you feel like the best version of you as well.
Second Place: Infinite Skin
Third Place: Catalyst Clinical Spa
Fourth Place: Hair Success Salon, Spa & MediSpa
Fifth Place: Posh Hair Studios & Spa
More:
Best of the Red River Valley 2019: Best Cosmetic/Esthetic Clinic - INFORUM
Posted in Testosterone
Comments Off on Best of the Red River Valley 2019: Best Cosmetic/Esthetic Clinic – INFORUM